SCHEMBL3598310

SCHEMBL3598310

Cc1cccc2c1ccn2CC(=O)NCCNCC1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
LMNA P02545 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
NPY5R Q15761 1/20 0.42
MAPT P10636 4/20 0.41
P2RX7 Q99572 2/20 0.41
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
BCHE P06276 1/20 0.40
HTR6 P50406 1/20 0.40
THRB P10828 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603868 0.87 ADORA2A (0.41) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3603572 0.86 MAPT (0.42) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3591246 0.83 LMNA (0.46) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3595022 0.82 HSD17B10 (0.55) LMNAALOX15TSHRMAPK1SMN1; SMN2
SCHEMBL3595662 0.82 GRIN2B (0.46) SMN1; SMN2NPY5RMAPTP2RX7BCHE
SCHEMBL3598309 0.81 SMN1; SMN2 (0.43) TSHRSMN1; SMN2MAPTHSD17B10BCHE
SCHEMBL3601868 0.79 BACE1 (0.47) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3600906 0.77 GRIN2B (0.47) NPC1LMNATSHRALDH1A1KDM4E
SCHEMBL3595148 0.77 KDM4E (0.45) NPC1LMNAALOX15TSHRMAPK1
SCHEMBL3599795 0.76 HDAC6 (0.47) NPC1ALOX15TSHRSMN1; SMN2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 NPC1 334/4885LMNA 4638/4885ALOX15 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.